The University of Chicago Header Logo

Connection

Walter M. Stadler to Prospective Studies

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Prospective Studies.
Walter M. Stadler
Connection Strength
0.578
Prospective Studies
  1. Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Support Care Cancer. 2022 Mar; 30(3):2803-2810.
    View in: PubMed
    Score: 0.112
  2. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
    View in: PubMed
    Score: 0.055
  3. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.045
  4. PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate. 2024 Feb; 84(3):292-302.
    View in: PubMed
    Score: 0.032
  5. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
    View in: PubMed
    Score: 0.029
  6. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 02; 20(1):1-10.
    View in: PubMed
    Score: 0.027
  7. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 10 20; 36(30):3064-3065.
    View in: PubMed
    Score: 0.022
  8. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061.
    View in: PubMed
    Score: 0.022
  9. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.022
  10. Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. Clin Transl Sci. 2018 07; 11(4):420-427.
    View in: PubMed
    Score: 0.022
  11. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
    View in: PubMed
    Score: 0.022
  12. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018 06; 16(3):213-218.
    View in: PubMed
    Score: 0.021
  13. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.021
  14. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
    View in: PubMed
    Score: 0.019
  15. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
    View in: PubMed
    Score: 0.018
  16. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60.
    View in: PubMed
    Score: 0.016
  17. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.015
  18. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43.
    View in: PubMed
    Score: 0.013
  19. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44.
    View in: PubMed
    Score: 0.011
  20. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8.
    View in: PubMed
    Score: 0.011
  21. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15; 22(6):1025-33.
    View in: PubMed
    Score: 0.008
  22. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
    View in: PubMed
    Score: 0.008
  23. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996 Oct; 156(4):1280-5.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.